|Bid||0.00 x 2200|
|Ask||0.00 x 1200|
|Day's Range||16.29 - 17.20|
|52 Week Range||6.51 - 37.99|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 7.69% and 7.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., August 04, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.